Cellceutix Announces Appointment of Vice President for Regulatory Affairs
16 sept. 2016 11h00 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - September 16, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones
13 sept. 2016 08h30 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - September 13, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Corporation to Present at Upcoming Conferences
07 sept. 2016 07h00 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - September 07, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran
30 août 2016 14h07 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - August 30, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
03 août 2016 09h30 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - August 03, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
21 juil. 2016 07h00 HE
|
Cellceutix
BEVERLY, MA --(Marketwired - July 21, 2016) - Cellceutix Corporation, (OTCQB: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis
18 juil. 2016 10h00 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - July 18, 2016) - Cellceutix Corporation, (OTCQB: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis
07 juil. 2016 08h30 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - July 07, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer
30 juin 2016 13h00 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - June 30, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis
15 juin 2016 11h45 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - June 15, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...